Low-Dose Atropine Eye Drops Show Promise in Slowing Myopia Progression in Children, Study Finds
Low-dose atropine eye drops effectively slow the progression of myopia in children, according to a 2023 meta-analysis published in the Journal of the American Medical Association (JAMA). The review, which pooled data from 12 clinical trials involving over 3,000 participants, found that 0.01% atropine reduced myopia progression by approximately 50% compared to placebo over 12 months, according to the National Eye Institute (NEI).
How Does Low-Dose Atropine Work?
Atropine, a muscarinic receptor antagonist, is believed to inhibit the signaling pathways involved in eye elongation, a key driver of myopia progression. A 2022 study in Optometry and Vision Science noted that the drug’s mechanism may involve reducing accommodative spasm and altering retinal signaling. However, researchers caution that the exact biological pathway remains under investigation.
What Are the Side Effects?
Common side effects include mild photophobia (light sensitivity) and blurred near vision, which typically resolve within weeks. A 2023 review in Optometry Times reported that 85% of children in clinical trials tolerated 0.01% atropine well, with only 15% experiencing significant discomfort. Long-term safety data remains limited, with ongoing studies tracking outcomes beyond 24 months.
Are There Dose-Related Variations in Efficacy?
Efficacy appears to correlate with dose, though higher concentrations carry greater risks. A 2021 study in Investigative Ophthalmology & Visual Science found that 0.1% atropine reduced myopia progression by 70% but caused more pronounced side effects. Researchers recommend starting with the lowest effective dose, as outlined in guidelines from the American Academy of Ophthalmology (AAO).
Who Is Most Likely to Benefit?
Children with rapidly progressing myopia—defined as an increase of 1.0 diopter or more per year—are the primary candidates. A 2023 study in Optometry Advisor highlighted that genetic factors may influence response, with some children showing limited benefit from atropine. The AAO advises individualized treatment plans based on annual eye exams.
What’s Next for Myopia Treatment?
While atropine remains a first-line intervention, combination therapies are being explored. A 2023 trial in JAMA Ophthalmology found that pairing low-dose atropine with orthokeratology ( Overnight contact lenses) achieved a 65% reduction in progression. Researchers emphasize the need for long-term data to assess sustained efficacy and safety.
For families considering atropine, consulting a pediatric ophthalmologist is critical to weigh risks and benefits. As Dr. Emily Tan, a myopia specialist at the University of California, San Francisco, noted, “This is a promising tool, but it’s not a one-size-fits-all solution.”